February 2024 21 of erysipelas), P. multocida serotype A, and toxinogenic P. multocida serotype D. A tetravalent Pasteurella OBP vaccine for cattle that is a formalinized bacterin of P. multocida serotypes A, D, and E plus M. haemolytica serotype A:1 is also commercially available. FUTURE PERSPECTIVES Extensive genetic, biochemical, and virulence studies of P. multocida and other Pasteurellaceae have provided valuable insights into the disease processes of these organisms in their natural hosts and have led to the development of new non-bacterin-based vaccines, several of which are now available commercially for animal use. With the impressive advances that have been made, we are at a cusp in regard to our understanding of the molecular virulence mechanisms of P. multocida pathogenesis. Pathogenomics and ribotyping, in particular, have greatly contributed to our ability to distinguish among the various clinical isolates for diagnostic purposes and epidemiological studies and have provided glimpses of the relatedness among the Pasteurellaceae. In addition to furthering our understanding of the role of capsule and LPS biosynthesis, antibiotic resistance, and PMT production in pasteurellosis, genome comparison has begun to identify additional virulence genes responsible for host specificity and other phenotypes. Major advances are on the horizon with the information gleaned from comparison of existing and additional genomes of P. multocida and other related Pasteurellaceae in the pipeline, as well as from in vivo transcriptional and protein expression profiling studies such as RNA-seq and proteomics technologies. Greater understanding of the molecular and immunologic mechanisms of pathogenesis will provide insights into the host-microbe interactions involved in chronic infection and the molecular basis of the transition from subclinical or chronic disease to acute, disseminated disease. These studies will also provide clues about the long-term sequelae of exposure to chronic or acute infections with these organisms. Our interactions with pets and other domestic and wild animals are unlikely to diminish in the future. Mounting evidence suggests that such contacts that result in P. multocida infection can lead to outcomes ranging from benign to disastrous. Considering the high prevalence of Pasteurella species as part of the microbiota of domestic and wild animals, it would be prudent for us to consider zoonotic transmission of P. multocida as a serious risk for infection. v ACKNOWLEDGMENTS • Some of the work reported here was supported by grants from the National • Institutes of Health (NIH/NIAID AI038396) and the U.S. Department of Agriculture (NRI 1999-02295) (to B.A.W.). REFERENCES For Full references please see: Leading Article (Pasteurella multocida)
RkJQdWJsaXNoZXIy OTc5MDU=